Health News from Medical News Today: Morphotek®, Inc. Announces Initiation Of MORAb-004 Phase II Study In Melanoma

Health News from Medical News Today Latest Health News and Medical News posted throughout the day, every day. Morphotek®, Inc. Announces Initiation Of MORAb-004 Phase II Study In Melanoma 3 Jun 2011, 8:00 am Morphotek®, Inc., a subsidiary of Eisai Inc., announced that it has commenced a multi-center, phase II study of MORAb-004 for the treatment of metastatic melanoma. The study will evaluate MORAb-004, a potentially first-in-class monoclonal antibody that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1), as a single agent therapy comparing its safety and therapeutic activity at two dosages... You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed.